Brexpiprazole Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg
Reference Brands: Rexulti®(US & EU)
Category:
Antipsychotropic Drugs
Brexpiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. This balanced activity helps modulate dopamine and serotonin pathways in the brain. It is used for the treatment of schizophrenia and as an adjunctive therapy for major depressive disorder (MDD) in adults, offering improved mood stabilization and reduced psychotic symptoms with a lower risk of extrapyramidal side effects.
Brexpiprazole Tablets is available in Tablets
and strengths such as 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Brexpiprazole Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Brexpiprazole Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Brexpiprazole tablets are FDA-approved in the United States for the treatment of schizophrenia and as an adjunctive therapy for major depressive disorder (MDD) in adults. In the European Union, Brexpiprazole is approved under brand names like Rxulti, primarily for schizophrenia, following centralized EMA procedures. Regulatory compliance includes GMP standards, comprehensive clinical data, and documentation on metabolic side effects, akathisia, and suicidality risks. U.S. submissions must meet FDA requirements including boxed warnings for elderly dementia-related psychosis. EMA approval mandates a full Risk Management Plan (RMP) and pharmacovigilance commitments. For dossier-ready Brexpiprazole tablets and sourcing options, visit Pharmatradz.com — your trusted B2B pharma platform.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing